) have been identified in the majority of ET and PMF patients who lack JAK2 and cMPL mutations, but are generally not found in PV patients. Compared with JAK2-and cMPL-mutated patients, CALR
MUT patients have higher platelet counts, lower hemoglobin and leukocyte counts, a lower risk of thrombosis 1 and a more favorable prognosis, but no difference in the rate of transformation to post-ET PMF. 2 Determination of clonality based on X-chromosome inactivation has helped to differentiate reactive processes from MPNs. However, prior to the discovery of MPN disease-defining mutations, it was reported that some patients with a clinical phenotype of ET had polyclonal hematopoiesis. 3 There are two widely used clonality assays based on X-chromosome inactivation (XCI), the HUMARA assay and the transcriptional-based clonality assay (TCA). The HUMARA clonality assay is based on assessing the DNA methylation status of adjacent CpG sites close to trinucleotide repeats in exon 1 of the human androgen receptor gene (AR). 4 Because some investigators observed unexpected results using the HUMARA assay, the second method was developed by our group based on analysis of transcripts of X-chromosome polymorphic genes subjected to X-chromosome inactivation, that is, TCA. 5, 6 Using both assays, discrepant data have been obtained in some females; however, TCA revealed only a single transcript in individual burst-forming units erythroid, while heterogeneous methylation at the AR locus was obtained by the HUMARA assay. 6 It has been reported recently that JAK2 V617F ET is more likely to have polyclonal hematopoiesis than CALR MUT ET; this study was conducted using the HUMARA assay. 7 We evaluated 96 ET, 33 PMF and 65 PV females for JAK2, cMPL and CALR mutation status, and using TCA we examined the existence of polyclonal hematopoiesis in our cohort of MPN females seen over the last three decades. We also report two previously undescribed exon 9 CALR mutations and our analyses of CALR MUT burden in granulocytes (GNC), CD3 + T-cells and some CD34 + progenitors. The 194 female patients with ET, PMF or PV were diagnosed according to the revised World Health Organization (WHO) criteria and had been treated with hydroxyurea or JAK2 inhibitors, but not pegylated interferon-α. Informed consent was obtained from all patients and 10 ml of peripheral blood was used for the study. Platelets and GNC were isolated according to previously published protocols. 5 Genomic DNA was isolated from GNC using the Puregene DNA purification kit (Gentra, MN, USA). JAK2 V617F and MPL W515L/K were detected by quantitative allele-specific PCR (qRT-PCR) 8 and CALR
MUT by semi-quantitative fragment analysis. 9 CALR MUT was categorized as CALR MUT type 1 (52-bp deletion; c.1092_1143del), CALR MUT type 2 (5-bp insertion; c.1154_1155insTTGTC) and other previously described variants. Samples with an unreported CALR profile were sequenced.
The frequency of JAK2 V617F was 57% (N = 55) in ET and 42% (N = 14) in PMF; all PV females were JAK2 V617F mutated. CALR MUT was present in 18% (N = 17) of ET and 39% (N = 13) of PMF. MPL W515L was found in only one PMF patient. Triple-negatives accounted for 25% (N = 24) of ET and 15% (N = 5) of PMF ( Figure 1a ). This distribution of mutations is consistent with previous studies. [9] [10] [11] To assess clonality, we first genotyped single nucleotide exonic polymorphisms from five X-chromosome genes subjected to X-chromosome inactivation (BTK; FHL1; IDS; G6PD; MPP1) using TaqMan allele-discrimination assays (Grand Island, NY, USA). Females heterozygous for any X-chromosome loci were considered informative for quantitative TCA (qTCA). Total RNA was isolated from GNC using Tri-Reagent (Molecular Research Center, Cincinnati, OH, USA) and allelic usage ratio of informative X-chromosome polymorphic genes determined. Aliquots of 200 ng of DNA-free RNA were reverse-transcribed using SuperScript VILO for qRT-PCR (Invitrogen, Grand Island, NY, USA). QRT-PCR was performed as described previously. 12 A ratio of ⩾ 80:20 was used to define clonality, accepting that~5% of normal females will have skewing of X-inactivation sufficient to be classified as clonal hematopoiesis. 6 
QTCA EVALUATIONS OF ET
Of 96 ET females, 80 were informative for TCA. Forty-seven had JAK2 V617F (30% mean allele burden) and 45 (96%) of these were clonal, whereas 12 (75%) of 16 CALR MUT ET females had clonal hematopoiesis (P = 0.032) (Figure 1b) . Of the 17 triple-negatives, 14 (82%) were clonal. In contrast to the study using the HUMARA assay, we found a higher frequency of clonal hematopoiesis in JAK2 V617F (96% versus 26%, Po0.001) and triple-negative ET (82% versus 9%, Po0.001), but a similar frequency of clonal CALR MUT ET. 7 QTCA EVALUATIONS OF PMF Thirty of 33 PMF females were informative for TCA; 12 of 13 (94%) with JAK2 V617F (39% mean allele burden) and 11 of 12 (92%) with CALR MUT were clonal (Figure 1c ). In four triple-negative PMF, three were clonal and one polyclonal. The single MPL W515L PMF female was clonal.
QTCA EVALUATIONS OF PV All 57 informative JAK2
V617F (44% mean allele burden) PV females were clonal by qTCA (Figure 1d ).
DISTRIBUTION OF CALR
MUT VARIANTS 
RELATIVE ALLELIC BURDEN OF CALR MUT
We also examined the relative allelic burden of CALR MUT in GNC, T-cells and CD34
+ progenitors using fragment analysis, a method which has a 3-5% allelic burden detection limit.
13 CD34 + cells and T-lymphocytes were sorted by fluorescence-activated cell sorting (FACS) using antibodies against CD34 or CD3 (FACS Vantage SE, BD Bioscience, San Jose, CA, USA). Among 29 CALR MUT ET and PMF female patients, the mean CALR MUT allelic burden was~50% in GNC and was undetectable in CD3 + T-cells. This is consistent with previously published data, which suggested that CALR MUT is a somatic mutation favoring differentiation to myeloid progenitors.
14 Among six ET female patients from whom CD34 + cells were available, the CALR MUT allelic burden was lower in CD34 + cells than in GNC (P = 0.005, Figure 2 ), similar to previously reported in JAK2 V617F PV patients. 15 In conclusion, we report analyses of 194 Ph-MPN females and confirm that polyclonal hematopoiesis exists in a minority of ET females. However, we found a marked difference between a 495% clonal prevalence in our JAK2 V617F ET cohort versus 26% reported by another group, and a similar discrepancy in triple-negative ET. 7 We submit this difference is very likely due to different XCI clonality assays, as methylation of the AR locus in the HUMARA assay does not always reflect the X-chromosome inactivation state. 6 The prevalence of clonal hematopoiesis was lower in CALR MUT than in JAK2 V617F ET in our cohort (75 versus 96%,) suggesting that CALR MUT clones have a weaker suppressive effect on residual normal hematopoietic stem cells than JAK2 mutated clones, which may contribute to the more benign course of CALR MUT ET. The receptor tyrosine kinase (RTK) FLT3 (Fms-like tyrosine kinase-3) is essential for the proliferation, differentiation and survival of hematopoietic cells. 1, 2 Mutations in the gene for FLT3 have been described in acute myeloid leukemia (AML) as internal tandem duplications (ITD) localized in the juxtamembrane (JM) domain and FLT3 tyrosine kinase domain (TKD) mutations amounting to 2-30% and 7-10% of patients, respectively. In patients with AML, FLT3-ITD confers an unfavorable prognosis. 3 In AML, recently discovered FLT3 mutations involve point mutations as well as short deletions in the JM domain, highlighting the importance for a deeper understanding and further studies of these aberrations. 4, 5 The FLT3 JM domain (Supplementary Figure 1a) is indeed the critical regulator region of receptor autoinhibition. 6 Kiyoi et al. 7 had shown constitutive activation of the FLT3 receptor by deletion of a stretch of amino acids in the JM domain, generally duplicated in FLT3-ITD.
In this study, during diagnostic screening for ITD and TKD mutations, we have identified and functionally characterized deletion mutations of FLT3 in the diagnostic work-up of over 6843 AML patients. Deletions were detected in seven patients (0.1%) with newly diagnosed or relapsed AML. All deletions detected by gene scan were in the range of 3-18 base pairs (Supplementary Table 1 and Figure 1a) . Subsequent sequencing revealed that all but one of these deletions, which was situated in the transmembrane domain, were in the JM domain, and were simple deletions (n = 5) or indels (n = 2). In three cases out of seven, 
